Skip Navigation

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines, Boosters & Additional Doses | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

 

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

Find a Research Lab

Research Lab Results for metabolomics

Displaying 1 to 2 of 2 results
Results per page:
  • Namandje N. Bumpus Lab

    Lab Website
    Principal Investigator:
    Namandje Bumpus, Ph.D.
    Medicine

    The Bumpus Laboratory uses mass spectrometry and molecular pharmacology-based approaches to study the biotransformation of clinically used drugs by the cytochromes P450s. Specifically, we are studying ways to define a role for cytochrome P450-dependent metabolites in the drug-induced acute liver failure that is associated with certain antiviral drugs used to treat HIV and hepatitis C. Our long-term goal is to gain information that can be used to develop therapies that are devoid of toxic events by preventing the formation of a toxic metabolite or by developing strategies for preventing toxicity using concomitant therapy.

    Research Areas: antiviral therapy, drug metabolism, mass spectrometry, HIV, drugs, cellular signaling, cytochromes P450, pharmacology, molecular pharmacology, hepatitis C, metabolomics
  • Saraswati Sukumar Lab

    Lab Website
    Principal Investigator:
    Saraswati Sukumar, Ph.D.
    Oncology

    Our lab is focused on using comprehensive gene expression, methylation and sequencing and metabolomics analysis to identify alterations in breast cancer, and exploiting these for early detection and therapy. Among deferentially expressed genes, our lab has focused on the HOX genes. HOX genes are intimately involved in the development of resistance to both chemotherapy and to agents targeting the estrogen receptor. Our work explores the alternate pathways that are activated by HOX proteins leading to this resistance and novel treatments to overcome resistance in both tissue culture and xenograft models. In addition, epigenetically silenced genes and a metabolic reprogramming in tumors also trigger novel early detection and therapeutic strategies. We are testing the utility of differentiation therapy through reactivating RAR-beta in breast cancer using histone deacetylase inhibitors with great success. Also, we are targeting enzymes involved in gluconeogenesis and glycolysis with small ...molecule FDA-approved antimetabolites to achieve antitumor effects. view more

    Research Areas: breast cancer, genetics
  1. 1
Create lab profile
Edit lab profile
back to top button